COSTEM | Next steps for improving dual CARs
Nirali Shah
• 15 Oct 2021
Nirali Shah, MD, National Cancer Institute, National Institutes of Health, Bethesda, MD, comments on the efficacy of dual chimeric antigen receptors (CARs), reporting that dual CARs demonstrate a lot of potential in the treatment of hematological malignancies, but that further research is required to improve the efficacy and persistence of CARs, and to prevent antigen escape. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.
